Approval · Notice of Compliance 32517 · 2024
TEVA-EZETIMIBE: Notice of Compliance 32517
Issued January 12, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 32517
- Date
- January 12, 2024
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Labelling Only
- Reason
- Update to labels
- Canadian reference product
- EZETROL
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-EZETIMIBE | Not yet assigned | — |
Medicinal ingredients
- EZETIMIBE 10 MG per TAB